Arkuda Therapeutics is a biotechnology company applying insights into lysosomal and microglial biology to drive the development of medicines to change the trajectory of neurodegenerative disease. Arkuda's lead program aims to correct progranulin deficiency and lysosomal dysfunction in patients with GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the progranulin (GRN) gene. The company is further exploring the therapeutic potential of its molecules in other neurodegenerative diseases where genetic links to dysfunction in progranulin biology have been established, including Alzheimer's Disease and Parkinson's Disease. Arkuda is backed by leading investors including Atlas Venture, Cormorant Asset Management, Pivotal bioVenture Partners, Pfizer Ventures, funds managed by Tekla Capital Management LLC, Mission BioCapital, Surveyor Capital (a Citadel company), and Eli Lilly and Company. To learn more visit www.arkudatx.com.
SOURCE Arkuda Therapeutics

https://www.arkudatx.com/

Watertown

Arkuda Therapeutics

Johnson & Johnson

Arkuda Therapeutics announced that Johnson & Johnson has exercised its option to acquire Arkuda's portfolio of lysosomal function enhancers in exchange for an upfront payment and opportunity for additional milestone payments. This acquisition signifies Johnson & Johnson's strategic move to leverage Arkuda's expertise and innovative approach to developing medicines for neurodegenerative diseases.

Johnson & Johnson exercises option to acquire Arkuda Therapeutics' lysosomal function enhancer portfolio

Description

Company Information

M&A Insights

Johnson & Johnson exercises option to acquire Arkuda Therapeutics' lysosomal function enhancer portfolio

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

M&A Insights

Company Information